FAM83B Polyclonal antibody
FAM83B Polyclonal Antibody for WB, ELISA
Host / Isotype
Rabbit / IgG
Reactivity
human
Applications
WB, ELISA
Conjugate
Unconjugated
Cat no : 26032-1-AP
Synonyms
Validation Data Gallery
Tested Applications
Positive WB detected in | MCF-7 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:500-1:3000 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
26032-1-AP targets FAM83B in WB, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | FAM83B fusion protein Ag22951 相同性解析による交差性が予測される生物種 |
Full Name | family with sequence similarity 83, member B |
Calculated molecular weight | 1011 aa, 115 kDa |
Observed molecular weight | 115 kDa |
GenBank accession number | BC112275 |
Gene symbol | FAM83B |
Gene ID (NCBI) | 222584 |
RRID | AB_3085837 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity purification |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol pH 7.3. |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
FAM83B, also known as C6orf143, belongs to the FAM83 family. FAM83B is an oncogene and promotes cell transformation through activating various pathway in different kinds of tumors. FAM83B over expressed in several kinds of malignant tumors, such as breast cancer, cervical cancer, endometrial cancer, pancreatic ductal adenocarcinoma, etc. Overexpression of FAM83B could promote the malignant biological behaviors of these tumors (PMID: 33423038, 36690987). The calculated molecular weight of FAM83B is 115 kDa.
Protocols
Product Specific Protocols | |
---|---|
WB protocol for FAM83B antibody 26032-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |